Get started
Author

Hans Wallberg

Observed names: H. Wallberg, Wallberg, H.
Institution: Medivir (Sweden)
ORCID: 0009-0000-8550-6366
Observed ORCID: 0009-0000-8550-6366
OpenAlex ID: A5072640010
Studies of the reactions between indole-2,3-diones (isatins) and 2-aminobenzylamine
2003 · Jan Bergman, Robert Engqvist, et al. · Tetrahedron · 104
Identification of MMP-12 Inhibitors by Using Biosensor-Based Screening of a Fragment Library
2008 · Helena Nordström, Thomas Gossas, et al. · Journal of Medicinal Chemistry · 53
Two-Carbon-Elongated HIV-1 Protease Inhibitors with a Tertiary-Alcohol-Containing Transition-State Mimic
2008 · Xiongyu Wu, Per Öhrngren, et al. · Journal of Medicinal Chemistry · 48
Microwave-Accelerated Synthesis of P1‘-Extended HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol in the Transition-State Mimicking Scaffold
2006 · Jenny K. Ekegren, Nina Ginman, et al. · Journal of Medicinal Chemistry · 44
A New Class of HIV-1 Protease Inhibitors Containing a Tertiary Alcohol in the Transition-State Mimicking Scaffold
2005 · Jenny K. Ekegren, Torsten Unge, et al. · Journal of Medicinal Chemistry · 44
HIV-1 Protease Inhibitors with a Transition-State Mimic Comprising a Tertiary Alcohol: Improved Antiviral Activity in Cells
2009 · A.K. Mahalingam, Linda Axelsson, et al. · Journal of Medicinal Chemistry · 37
Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: Use of cyclopentane and cyclopentene P2-motifs
2007 · Marcus Bäck, Per-Ola Johansson, et al. · Bioorganic & Medicinal Chemistry · 36
Synthesis, X-ray Analysis, and Biological Evaluation of a New Class of Stereopure Lactam-Based HIV-1 Protease Inhibitors
2012 · Xiongyu Wu, Per Öhrngren, et al. · Journal of Medicinal Chemistry · 23
Synthesis of P1′-Functionalized Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol
2014 · Maria De Rosa, Johan Unge, et al. · Journal of Medicinal Chemistry · 18
Design and Synthesis of P1–P3 Macrocyclic Tertiary-Alcohol-Comprising HIV-1 Protease Inhibitors
2013 · Advait Joshi, Jean-Baptiste Véron, et al. · Journal of Medicinal Chemistry · 18
PDF
Variations of the P2 group in HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold
2006 · Jenny K. Ekegren, Johan Gising, et al. · Organic & Biomolecular Chemistry · 16
Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application
2012 · Bart Kesteleyn, Katie Amssoms, et al. · Bioorganic & Medicinal Chemistry Letters · 15
Synthesis of the Hepatitis B Nucleoside Analogue Lagociclovir Valactate
2011 · Martin Brodszki, Birthe Bäckström, et al. · Organic Process Research & Development · 14
Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors
2009 · Jenny Adrian Meredith, Hans Wallberg, et al. · European Journal of Medicinal Chemistry · 14
HIV-1 protease inhibitors with a tertiary alcohol containing transition-state mimic and various P2 and P1′ substituents
2011 · Per Öhrngren, Xiongyu Wu, et al. · MedChemComm · 13
The advantage of biosensor analysis over enzyme inhibition studies for slow dissociating inhibitors – characterization of hydroxamate-based matrix metalloproteinase-12 inhibitors
2012 · Thomas Gossas, Helena Nordström, et al. · MedChemComm · 7
Does a Fast Nuclear Magnetic Resonance Spectroscopy- and X-Ray Crystallography Hybrid Approach Provide Reliable Structural Information of Ligand-Protein Complexes? A Case Study of Metalloproteinases
2009 · Johan Isaksson, Susanne Nyström, et al. · Journal of Medicinal Chemistry · 6
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
2024 · Ruth Plummer, Alastair Greystoke, et al. · Journal of Hepatocellular Carcinoma · 4
PDF
Two-Carbon-Elongated HIV-1 Protease Inhibitors with a Tertiary-Alcohol-Containing Transition-State Mimic
2008 · Xiongyu Wu, Per Öhrngren, et al. · Journal of Medicinal Chemistry · 2
PDF
986P Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study
2024 · H. Chon, J. Heo, et al. · Annals of Oncology · 1
PDF
First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC).
2024 · Maria Reig, T.R. Jeffry Evans, et al. · Journal of Clinical Oncology · 1
PDF
Studies of the Reactions Between Indole‐2,3‐diones (Isatins) and 2‐Aminobenzylamine.
2003 · Jan Bergman, Robert Engqvist, et al. · ChemInform · 1
Supplementary Data1 from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
2026 · Hong Jae Chon, Jeong Heo, et al.
Data from A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
2026 · Hong Jae Chon, Jeong Heo, et al.
A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma
2026 · Hong Jae Chon, Jeong Heo, et al. · Clinical Cancer Research
Works count: 33
Citation count: 519
H-index: 14
I10-index: 15
Year
Topic
Type